S. Swann

发表

Development of Orally Efficacious Allosteric Inhibitors of TNFα via Fragment-Based Drug Design.

S. C. Panchal, Philip B. Cox, P. Hajduk, 2020, Journal of medicinal chemistry.

A unified, probabilistic framework for structure- and ligand-based virtual screening.

Scott P. Brown, P. Hajduk, S. Swann, 2011, Journal of medicinal chemistry.

Biochemical and biophysical characterization of unique switch pocket inhibitors of p38α.

P. Hajduk, S. Swann, Chaohong Sun, 2010, Bioorganic & medicinal chemistry letters.

Design of a systemic small molecule clinical STING agonist using physics-based simulations and artificial intelligence

Bryce K. Allen, S. Swann, W. Sherman, 2022, bioRxiv.

Structure-based design of selective agonists for a rickets-associated mutant of the vitamin d receptor.

S. Swann, M. Farach-Carson, J. Bergh, 2002, Journal of the American Chemical Society.

Design of a systemic small molecule clinical STING agonist using physics-based simulations and artificial intelligence

Bryce K. Allen, S. Swann, W. Sherman, 2022, bioRxiv.

Critical Aspartic Acid Residues in Pseudouridine Synthases*

S. Swann, J. Paulson, E. Mueller, 1999, The Journal of Biological Chemistry.

Rational design of vitamin D3 analogues which selectively restore activity to a vitamin D receptor mutant associated with rickets.

S. Swann, M. Farach-Carson, J. Bergh, 2002, Organic letters.

Role of cysteine residues in pseudouridine synthases of different families.

S. Swann, E. Mueller, C. Spedaliere, 1999, Biochemistry.

Fragment-based discovery of potent inhibitors of the anti-apoptotic MCL-1 protein.

Chang Park, S. Swann, A. Petros, 2014, Bioorganic & medicinal chemistry letters.

Labeled Ligand Displacement: Extending NMR-Based Screening of Protein Targets.

P. Hajduk, S. Swann, A. Petros, 2010, ACS Medicinal Chemistry Letters.